DECLARE-TIMI 58
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 17,160 patients with type 2 diabetes, dapagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.
N
17.160
Design
Double-blind RCT
Endpunkt
CV death/HF hospitalisation and MACE (co-primary)
Relevanz
2
ErgebnisCV death or HF hospitalisation HR 0.83; MACE not significantly reduced.
Wiviott SD, et al. N Engl J Med. 2019;380(4):347-357. 10.1056/NEJMoa1812389
Diskussion & Kritik
The largest SGLT2i outcomes trial, with the most primary-prevention patients — benefit was mainly heart-failure prevention rather than atherothrombotic events.